CNSA & ICCN 2025 Congress |18-21 Jun 2025 | Adelaide Convention Centre | Global Voices, Local Actions: from inspiration to implementation

About the Breakfast Sessions

Breakfast sessions are available for all delegates to attend (excluding exhibitors) and spaces are limited and strictly on a first come first serve basis. A stand-up buffet breakfast will be provided and available 30 minutes before the sessions commence. 

Please click on the links below for more information on the breakfast topics. In order to attend the breakfast sessions, you will be required to indicate your attendance as part of your registration form.

Thursday 19 June

Friday 20 June
Breakfast One - La Roche Posay Breakfast One - Gilead
Breakfast Two - AstraZeneca Breakfast Two - Lilly
Breakfast Three - Astellas Breakfast Two - Slater and Gordon 

 

Thursday 19 June

Breakfast Session One

Title: La Roche-Posay: A Global Commitment to Skin Health in Oncology - From Thermal Springs to Your Clinic

Time: 0730 - 0830 - A stand-up buffet breakfast will be provided and available 30 minutes before the sessions commence (7.00am - 7.30am). This will be served outside the meeting room.

Presenters: TBC

Description: 

Discover how La Roche-Posay is revolutionising skin care for cancer patients worldwide. This session takes you on a journey from the brand's rich heritage and the supportive Thermal Centre in France, to the impactful "Fight with Care" initiative in Australia. Learn about the development and timeline of vital Australian and New Zealand oncology guidelines for managing skin toxicities. Plus, explore local partnerships with Princess Alexandra Hospital and Ramsay nurses. Join a lively panel discussion, sharing real-world case studies. Walk away with practical knowledge you can implement immediately in your clinical practice.

 

Breakfast Session Two 

Title: Survivorship for patients with metastatic cancers: comprehensive care they deserve

Time: 0730 - 0830 - A stand-up buffet breakfast will be provided and available 30 minutes before the sessions commence (7.00am - 7.30am). This will be served outside the meeting room.

Facilitator/s: Justin Hargreaves (CNSA Nurse Practitioner) & Panel: TBC

Description: 

Empowering metastatic patients by offering them the tools, resources and support systems to maintain a high quality of life despite the challenges with a focus on metastatic breast cancer. 

 

Breakfast Session Three

Title: TBC

Time: 0730 - 0830 - A stand-up buffet breakfast will be provided and available 30 minutes before the sessions commence (7.00am - 7.30am). This will be served outside the meeting room.

Presenters: TBC

Description: TBC

 

Friday 20 June

 

Breakfast Session One

Title: The Role of Trodelvy in Caring for Patients with Metastatic Triple-Negative Breast Cancer

Time: 0730 - 0830 - A stand-up buffet breakfast will be provided and available 30 minutes before the sessions commence (7.00am - 7.30am). This will be served outside the meeting room.

Presenters: Dr Rohit Joshi and Michael Fitzgerald

Description: 

This symposium is designed for Oncology nurses who play a critical role in the care of patients with metastatic triple-negative breast cancer (mTNBC). With limited treatment options available for this aggressive disease, Trodelvy® (sacituzumab govitecan) has emerged as a key advancement, offering improved survival outcomes for patients who have progressed on prior therapies.1
Nursing experts and oncology specialists will discuss the clinical benefits of Trodelvy, and its impact on patient survival, as demonstrated in the ASCENT trial. The session will emphasise the nurse’s role in treatment administration, patient education, and proactive management of side effects to optimise patient outcomes.
Practical insights on recognising and managing adverse events, supporting adherence, and addressing patient concerns will also be shared. The symposium will highlight the importance of time in treatment decisions, focusing on quality of life and patient-centred care.
By the end of this session, nurses will gain valuable knowledge on integrating Trodelvy into treatment plans, enhancing patient support, and improving the overall care experience for individuals living with mTNBC.
 
1Bardia A et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med 2021; 384: 1529-41.


Breakfast Session Two

Title: Evolution of treatment pathways for HR+, HER2- EBC patients

Time: 0730 - 0830 - A stand-up buffet breakfast will be provided and available 30 minutes before the sessions commence (7.00am - 7.30am). This will be served outside the meeting room.

Presenters: TBC

Description: TBC

 

Breakfast Session Three

Title: Lung Cancer: When Smoking Doesn’t Matter… Thinking Beyond a Smoking History

Time: 0730 - 0830 - A stand-up buffet breakfast will be provided and available 30 minutes before the sessions commence (7.00am - 7.30am). This will be served outside the meeting room.

Presenters: 
Tracy Madden – Senior Legal Counsel, Slater and Gordon Lawyers
Raelene Lingam – Senior Legal Counsel, Slater and Gordon Lawyers
Emily Archer – Legal Counsel, Slater and Gordon Lawyers

Description: 

This session will cover common and lesser-known causes of lung cancer; a focus on asbestos exposure and lung cancer; silica and lung cancer and what the future holds; lung cancer screening and what it means; and case studies, future predictions and Q&A.